XORTX Therapeutics Inc. (XRTX)
| Market Cap | 2.58M -43.4% |
| Revenue (ttm) | n/a |
| Net Income | -3.74M |
| EPS | -2.83 |
| Shares Out | 1.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,147 |
| Open | 1.530 |
| Previous Close | 1.560 |
| Day's Range | 1.410 - 1.540 |
| 52-Week Range | 1.360 - 7.050 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About XRTX
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for th... [Read more]
Financial Performance
Financial StatementsNews
Xortx Therapeutics outlines anticipated clinical trial application for XRx-026
Xortx Therapeutics (XRTX) provided an outline of its anticipated clinical trial application, or CTA, submission to Health Canada for the XRx-026 gout program. The filing supports the company’s planned...
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
● Clinical Trial Application planned for filing with Health Canada, extending the Company's international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE...
Xortx Therapeutics announces planned FDA IND submission for XRx-026
XORTX Therapeutics (XRTX) outlines its anticipated Investigational New Drug application, IND, submission to the U.S. Food and Drug Administration, FDA, for the XRx-026 gout program. XORTX’s drug devel...
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company's regulatory path toward NDA filing for gout program XRx-026 Investigat...
Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo
Xortx Therapeutics (XRTX) announced the launch of production of drug material and tablet manufacturing to support the company’s XRx-026 program for the treatment of gout. This manufacturing supports a...
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ●
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TS...
Xortx Therapeutics terminates investor relations, marketing agreement
Xortx Therapeutics (XRTX) terminated its previously announced investor relations and marketing agreement dated May 13 with IR Agency LLC. The IR agreement had a 90-day term commencing May 18 and…
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused...
XORTX Announces Director Resignation
CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Appoints New Director
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
Xortx Therapeutics announces Mika Grasso as co-CEO
Xortx Therapeutics (XRTX) announced the addition of Mika Grasso as co-CEO responsible for finance and public markets. Grasso has served as a director of the company since March 24. Grasso…
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Announces Closing of US$5 Million Public Offering
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exc...
Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
Xortx Therapeutics (XRTX) announced the pricing of a public offering of 2.66M common shares at an offering price of $1.88 for gross proceeds of $5M, prior to deducting placement agent’s…
XORTX Announces US$5 Million Public Offering
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused...
Xortx Therapeutics meets Nasdaq continued listing requirements
XORTX Therapeutics (XRTX) announces that it has received a letter of compliance from the Nasdaq Stock Market’s Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires...
Xortx Therapeutics to effect 5-for-1 share consolidation on April 6
XORTX Therapeutics (XRTX) announces that, further to its news release of March 26, the implementation of its share consolidation on the basis of one new common share for every five…
XORTX Confirms Effective Date of Share Consolidation
CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Announces Results of Annual and Special Meeting of Shareholders
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Announces Change of Effective Date of Share Consolidation
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
XORTX Announces Share Consolidation
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focus...
Xortx Therapeutics announces three new director nominees
XORTX Therapeutics (XRTX) announces that, in connection with its upcoming annual and special meeting of shareholders to be held on March 24, three new director nominees will be proposed for…